Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
3.770
+0.130 (3.57%)
At close: Mar 31, 2026, 4:00 PM EDT
3.700
-0.070 (-1.86%)
Pre-market: Apr 1, 2026, 4:29 AM EDT

Aardvark Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-57.59-20.59-7.21-7.21
Depreciation & Amortization
0.040.02--
Stock-Based Compensation
3.950.440.310.31
Other Adjustments
-0.920.471.151.15
Changes in Accounts Payable
0.240.80.780.78
Changes in Accrued Expenses
6.421.39-0-0
Changes in Other Operating Activities
-6.3-0.61-0.86-0.86
Operating Cash Flow
-54.17-18.09-5.82-5.82
Capital Expenditures
-0.1-0.11--
Purchases of Investments
-129.6-11.89--
Proceeds from Sale of Investments
80.03---
Investing Cash Flow
-49.67-12--
Issuance of Common Stock
91.640.33--
Net Common Stock Issued (Repurchased)
91.640.33--
Issuance of Preferred Stock
-85--
Net Preferred Stock Issued (Repurchased)
-85--
Other Financing Activities
-2.39-3.34--
Financing Cash Flow
89.2581.99--
Net Cash Flow
-14.5951.91-5.82-5.82
Free Cash Flow
-54.27-18.2-5.82-5.82
Free Cash Flow Per Share
-2.77-4.55-1.47-1.50
Levered Free Cash Flow
-57.29-19.11-7.29-13.65
Unlevered Free Cash Flow
-62.43-21.31-7.5-11.44
Updated Mar 23, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q